Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    The stratum corneum is the target of CMS nanocarriers after topical application in healthy and inflamed mouse skin (2016)

    Art
    Vortrag
    Autoren
    Radbruch, M (WE 12)
    Pischon, H (WE 12)
    Ostrowski, A (WE 12)
    Unbehauen, M
    Volz, P
    Alexiev, U
    Haag, R
    Gruber, A.D. (WE 12)
    Mundhenk, L (WE 12)
    Kongress
    Int.Conference on Dermal Drug Delivery by Nanocarriers 2016
    Berlin, Deutschland, 14. – 16.03.2016
    Quelle
    Nanomedicine : nanotechnology, biology, and medicine; 13(1) — S. 317–327
    ISSN: 1549-9642
    Sprache
    Englisch
    Verweise
    DOI: 10.1016/j.nano.2016.09.004
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    Gebäude 12
    14163 Berlin
    Tel.+49 30 838 62450 Fax.+49 30 838 62522

    Abstract / Zusammenfassung

    Inflammatory disorders of the skin pose particular therapeutic challenges due to complex structural and functional alterations of the skin barrier. Penetration of several anti-inflammatory drugs is particularly problematic in psoriasis, a common dermatitis condition with epidermal hyperplasia and hyperkeratosis. Here, we tested in vivo dermal penetration and biological effects of dendritic core-multishell-nanocarriers (CMS) in a murine skin model of psoriasis and compared it to healthy skin. In both groups, CMS exclusively localized to the stratum corneum of the epidermis with only very sporadic uptake by Langerhans cells. Furthermore, penetration into the viable epidermis of nile red as a model for lipophilic compounds was enhanced by CMS. CMS proved fully biocompatible in several in vitro assays and on normal and psoriatic mouse skin. The observations support the concept of CMS as promising candidates for drug delivery in inflammatory hyperkeratotic skin disorders in vivo.